NCT00003515 - Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 1996

Primary Completion Date

January 3, 1997

Study Completion Date

January 3, 1997

Conditions

Primitive Neuroectodermal Tumor

Interventions

DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston